ESRD (end-stage renal disease)

This study tested whether a smart app called Weiyin Health could improve follow-up care for 223 adults on peritoneal dialysis for kidney failure. One group used the app for reminders, AI questions, and risk alerts, while the other got standard care via WeChat and phone calls. The…

This Phase 3 trial tested a new drug called AP301 in 474 Chinese adults on dialysis who had high phosphorus levels. Participants took AP301, a low dose of AP301, or the standard drug sevelamer carbonate with meals. The main goal was to see how well AP301 lowers phosphorus compare…

This trial asks whether giving dialysis patients four doses of a double-strength hepatitis B vaccine offers better protection than the standard three doses. People with kidney failure on dialysis often respond weakly to vaccines, leaving many unprotected. The study will compare a…

This completed study at Huashan Hospital looked at data from 778 adults on long-term hemodialysis. Researchers used artificial intelligence to build models that could give early warnings about inadequate dialysis and help diagnose complications like heart disease. The goal is to …

This completed pilot study tested whether the HemoCept device can accurately measure fluid removal during dialysis in 26 adults with end-stage kidney disease. Researchers compared device readings before and after dialysis to changes in dry weight. The goal is to see if this non-i…

This pilot study tested a device called HemoCept in 12 adults with end-stage kidney disease on dialysis. The goal was to see if the device could accurately track changes in hydration during fluid removal. Researchers compared device readings to changes in dry weight before, durin…